CTI BioPharma (CTIC) Misses Q3 EPS by 7c

November 5, 2015 4:14 PM

CTI BioPharma (NASDAQ: CTIC) reported Q3 EPS of ($0.19), $0.07 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $1 million versus the consensus estimate of $16.3 million.

For earnings history and earnings-related data on CTI BioPharma (CTIC) click here.



Next Articles